The Biktarvy patient assistance program is the most direct path to free Biktarvy for uninsured US patients with HIV. Run by Gilead Sciences under the brand name Gilead Advancing Access, the program provides Biktarvy at no cost to qualifying patients and operates a separate copay coupon program for commercially insured patients. SunnyPharma is an independent health education platform serving cost-burdened patients navigating medication access, and this page documents Gilead Advancing Access, the Biktarvy copay card, state ADAP programs, and Medicare access pathways — with step-by-step enrollment instructions for each.
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) carries a list price of $4,216 per month in the US, but very few uninsured patients actually pay that amount. The programs on this page exist specifically to close the gap between list price and what patients can afford.
What Is the Biktarvy Patient Assistance Program?
The term “Biktarvy patient assistance program” most commonly refers to Gilead Advancing Access, a manufacturer program run by Gilead Sciences — the company that makes Biktarvy. The program has two main tracks:
| Track | Who It’s For | Benefit |
|---|---|---|
| Patient Assistance Program (PAP) | Uninsured or underinsured patients who meet income limits | Free Biktarvy, shipped to your doctor’s office or pharmacy in 90-day supplies |
| Copay Coupon Program | Commercially insured patients with a Biktarvy copay | Copay reduced to as little as $0/month (annual benefit cap applies) |
Both tracks are administered through the same helpline and case management system. Your HIV specialist or primary care provider can initiate enrollment on your behalf, which is required for the PAP track.
Gilead Advancing Access: Free Biktarvy for Qualifying Patients
The Patient Assistance Program (PAP) provides free Biktarvy directly to patients who have no insurance, whose insurance does not cover Biktarvy, or who have exhausted their coverage benefits. Eligibility is based on three main criteria:
Eligibility at a glance: US residency · Valid Biktarvy prescription · Inadequate or no insurance coverage for Biktarvy · Household income within program guidelines (generally up to 500% of the Federal Poverty Level, approximately $75,300 for a single person in 2026)
Gilead does not publish a single fixed income cutoff. Income thresholds are reviewed and adjusted annually and vary by household size. Patients whose income exceeds published limits may still qualify under exceptional-circumstances review. Your Gilead case manager will confirm current thresholds when you call.
What the Program Provides
Approved patients receive Biktarvy at no cost, typically dispensed for a 90-day supply at a time. The medication is shipped to your prescribing physician’s office or a designated specialty pharmacy. Participants are re-evaluated periodically to confirm continued eligibility, typically on an annual basis.
Who Is Not Eligible
Important limitation: Patients enrolled in Medicare Part D, Medicaid, or any other federally funded healthcare program are generally not eligible for the PAP under federal law. Separate assistance pathways exist for government-insured patients — see the Medicare and ADAP sections below.
Biktarvy Copay Card: Reducing Costs with Commercial Insurance
If you have private (commercial) health insurance and Biktarvy is covered but your copay is high, Gilead’s Copay Coupon Program can reduce your monthly out-of-pocket cost to as little as $0. The card functions similarly to a manufacturer coupon applied at the pharmacy counter.
Key details for the copay card:
| Feature | Detail |
|---|---|
| Eligible insurance | Commercial/private insurance only |
| Medicare/Medicaid | Not eligible — federal anti-kickback rules prohibit this |
| Annual benefit cap | Program terms set a maximum annual savings amount (confirmed at enrollment) |
| Income requirement | None for the copay card |
| How to enroll | Call 1-800-226-2056 or enroll through your specialty pharmacy |
Copay card and Medicare do not mix. Using a manufacturer copay card when you are a Medicare beneficiary is prohibited under federal law and can expose you and your pharmacist to legal risk. If you have Medicare, use the Extra Help or ADAP pathways described below instead.
AIDS Drug Assistance Programs (ADAP)
Every US state and territory operates an AIDS Drug Assistance Program (ADAP), funded through the federal Ryan White HIV/AIDS Program. ADAPs provide HIV medications — including Biktarvy — to low-income individuals who are uninsured or underinsured, regardless of immigration status in many states.
ADAPs are among the most important access tools for people living with HIV in the US, particularly because:
· ADAPs can serve Medicare and Medicaid beneficiaries, filling coverage gaps that manufacturer programs cannot
· They are not affected by the federal anti-kickback statute that limits manufacturer copay cards
· Many ADAPs also help enrollees obtain health insurance through premium payment assistance
To find your state’s ADAP and determine eligibility, contact the National Alliance of State & Territorial AIDS Directors (NASTAD) or call the HIV/AIDS hotline at 1-800-HIV-0440. Your HIV clinic’s social worker or case manager can also initiate an ADAP referral directly.
Medicare Options for Biktarvy Coverage
If you have Medicare, you have two primary pathways to reduce Biktarvy costs — and in many cases, both can be used together.
Medicare Extra Help (Low Income Subsidy)
Medicare Extra Help is a federal program that dramatically reduces Part D prescription drug costs for Medicare beneficiaries with limited income and resources. Biktarvy, as a Part D drug, is eligible. Qualifying for Extra Help can reduce your share of Biktarvy’s cost to a modest fixed copay per fill.
To apply for Extra Help, visit the Social Security Administration’s Extra Help page or call the SSA at 1-800-772-1213. Eligibility is based on income and resources, not age.
State ADAP as a Medicare Supplement
Many state ADAPs have specific components designed to help Medicare Part D beneficiaries pay premiums, deductibles, and cost-sharing amounts that Extra Help does not fully cover. This combination — ADAP covering the gaps left by Medicare — is used routinely by HIV-positive Medicare beneficiaries across the US. Ask your care team or ADAP case worker about the Medicare Savings Benefit component of your state’s program.
How to Apply: Step-by-Step
The most direct route to the Gilead Advancing Access program is through your prescribing physician’s office. Your doctor’s office will often have experience with the enrollment process and can initiate it on your behalf.
Tell your HIV specialist or primary care physician that you cannot afford Biktarvy and want to explore patient assistance. They can confirm whether you are a candidate and begin the enrollment process. Many practices have an in-house patient assistance coordinator who handles this routinely.
Reach the program directly at 1-800-226-2056 (Monday–Friday, 9 AM–8 PM ET). A case manager will confirm your eligibility, explain the required documents, and guide both you and your provider through enrollment. Ask explicitly about a bridge supply if you need medication immediately.
You will typically need: proof of US residency (state ID, utility bill), proof of income (recent tax return, pay stubs, or letter of unemployment), insurance card or documentation of no coverage, and a completed prescription from your doctor.
The physician portion of the application includes confirming the diagnosis, prescribing Biktarvy, and attesting to your clinical need. Many practices handle this routinely through their in-house patient assistance coordinator.
Complete applications are typically processed within 5–10 business days. If you need Biktarvy urgently while your application is being reviewed, ask your care team about bridge supplies or emergency ADAP enrollment for interim coverage.
Also available through your pharmacy: Some specialty pharmacies that dispense Biktarvy have patient assistance coordinators on staff who can initiate Gilead Advancing Access enrollment on your behalf. Ask your pharmacist whether this service is available.
Comparing Your Options at a Glance
| Program | Best For | Medicare OK? | Income Limit? | Contact |
|---|---|---|---|---|
| Gilead Advancing Access PAP | Uninsured / underinsured | Generally no | Yes (FPL-based) | 1-800-226-2056 |
| Gilead Copay Card | Commercial insurance copay | No | No | 1-800-226-2056 |
| State ADAP | Uninsured, underinsured, Medicare gaps | Yes | Yes (varies by state) | 1-800-HIV-0440 |
| Medicare Extra Help | Medicare Part D beneficiaries | Yes | Yes (SSA-determined) | 1-800-772-1213 |
Related Cluster Pages
If your situation differs from the manufacturer-PAP pathway above, the following SunnyPharma guides may apply:
- Biktarvy cost: full pricing guide → — insured, Medicare, and Medicaid pricing scenarios for 2026
- Biktarvy cost without insurance → — full guide to all 6 program pathways including ADAP, Medicaid, Ryan White, 340B, ACA, and nonprofit foundations
- Biktarvy cost in Mexico → — for patients considering cross-border options
- HIV Medications cluster → — all SunnyPharma HIV medication access guides
Frequently Asked Questions
What is the Biktarvy patient assistance program?
Gilead Advancing Access is the manufacturer-sponsored patient assistance program for Biktarvy, run by Gilead Sciences. It provides free Biktarvy to qualifying patients who are uninsured or whose insurance does not cover the medication, and whose household income falls within program guidelines based on the Federal Poverty Level. The program also operates a separate copay coupon track for commercially insured patients.
Who qualifies for free Biktarvy through Gilead Advancing Access?
To qualify for free Biktarvy through Gilead Advancing Access, you generally need to be a US resident, have a valid prescription, lack adequate insurance coverage for Biktarvy, and meet income eligibility requirements. Income thresholds are based on the Federal Poverty Level and are updated annually. Your prescribing physician must enroll in the program on your behalf. Patients above the published threshold may still qualify under exceptional-circumstances review.
How do I apply for the Biktarvy patient assistance program?
To apply, contact Gilead Advancing Access at 1-800-226-2056. A case manager will guide you and your doctor through the enrollment process. You will need to provide proof of income, proof of residence, and insurance information. Your healthcare provider must complete a portion of the application. Once approved, Biktarvy is shipped directly to your physician’s office or a designated specialty pharmacy in 90-day supplies.
What is the income limit for the Gilead PAP?
Gilead evaluates PAP eligibility on a case-by-case basis. The published guideline is income up to 500% of the Federal Poverty Level — approximately $75,300 for a single person in 2026 — but Gilead reviews each application individually. Patients above this threshold may still qualify under exceptional-circumstances review depending on geography, household size, and other costs. Income thresholds are reviewed and adjusted annually.
Does the Biktarvy copay card work with Medicare?
No. Gilead’s copay card (Copay Coupon Program) is for commercially insured patients only. Federal law prohibits manufacturer copay cards from being used with Medicare, Medicaid, or other government health programs. If you have Medicare, see the Medicare Extra Help (Low Income Subsidy) or ADAP options described on this page.
What if I have Medicare and cannot afford Biktarvy?
Medicare beneficiaries who cannot afford Biktarvy have several options: Medicare Extra Help (Low Income Subsidy) can significantly reduce Part D drug costs to a modest fixed copay per fill; state AIDS Drug Assistance Programs (ADAPs) can cover gaps not met by Medicare, including premiums and cost-sharing; and Gilead Advancing Access may provide free medication to Medicare beneficiaries who meet income requirements. Contact 1-800-HIV-0440 to find local ADAP resources.
How long does it take to receive Biktarvy through patient assistance?
Gilead Advancing Access typically processes complete applications within 5 to 10 business days. If you need Biktarvy urgently while your application is pending, ask your healthcare provider about bridge supplies or whether your state ADAP can provide interim coverage. Many states have emergency ADAP enrollment pathways for HIV-positive patients facing imminent treatment interruption.
Can I apply to Gilead PAP and state ADAP at the same time?
Yes. Gilead PAP and state ADAP are not mutually exclusive — they are separate programs administered by different entities (Gilead is the manufacturer; ADAP is a state government program funded by the federal Ryan White Program). Apply to both simultaneously to maximize coverage and reduce delay. Some patients use both programs together, with each covering different parts of treatment. Notify each program if you are accepted to the other.
What happens if Gilead PAP denies my application?
Request a written explanation of the denial first. Common reasons include incomplete documentation or income above threshold. If income was calculated incorrectly, request a supervisor review. If income is above threshold but you have high other medical costs, ask Gilead about exceptional-circumstances review. State ADAP applies parallel eligibility rules — apply to ADAP if not already enrolled. Federally Qualified Health Centers and Ryan White clinics can also dispense Biktarvy via 340B pricing for patients who don’t qualify for manufacturer programs.
What is a bridge supply and how do I get one?
A bridge supply is a temporary supply of Biktarvy provided by Gilead Advancing Access while your full PAP application is being processed. It prevents treatment interruption during the 5 to 10 business-day review window. When you call 1-800-226-2056, explicitly ask: “Can I receive a bridge supply while my application is being reviewed?” Bridge supplies are typically dispensed for 1 to 2 weeks and are at no cost.
Does the Biktarvy copay card have an annual benefit cap?
Yes. Gilead’s Copay Coupon Program has an annual benefit cap set by program terms — the exact amount is confirmed at enrollment and may change year-to-year. The cap is typically high enough to cover full Biktarvy copays for most commercially insured patients across a calendar year. Patients should track their annual benefit use and reapply each calendar year to maintain coverage.
How we reviewed this article:
Ray Ashton researched and wrote this article using primary sources from Gilead Sciences (Gilead Advancing Access program documentation, Biktarvy prescribing information, wholesale acquisition cost data), HRSA (Ryan White HIV/AIDS Program and ADAP), CMS (Medicaid and Medicare Part D), the Social Security Administration (Extra Help), NASTAD, KFF, HIV.gov, and the CDC. Dr. Neha Mishra reviewed the medical, regulatory, and patient-pathway content for clinical accuracy and patient-safety completeness. Program eligibility criteria and contact numbers reflect publicly available program documentation; last verified May 2026.
Read our editorial policy →Sources & References
- Gilead Sciences. BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide) Prescribing Information. Accessed May 2026.
- Gilead Sciences. BIKTARVY Cost Information — Wholesale Acquisition Cost. As of January 1, 2026.
- Gilead Sciences. Gilead Advancing Access — Patient Support Programs. Accessed May 2026.
- Health Resources and Services Administration. AIDS Drug Assistance Programs (ADAP) — Ryan White Part B. Accessed May 2026.
- Health Resources and Services Administration. Ryan White HIV/AIDS Program — Overview. Accessed May 2026.
- Health Resources and Services Administration. Find HIV Care — Ryan White Clinic Locator. Accessed May 2026.
- NASTAD. ADAP Watch — National Snapshot of State ADAP Programs. Accessed May 2026.
- NASTAD. National Alliance of State and Territorial AIDS Directors — State Resources. Accessed May 2026.
- Social Security Administration. Medicare Extra Help (Low Income Subsidy). Accessed May 2026.
- Centers for Medicare and Medicaid Services. Medicaid Eligibility. Accessed May 2026.
- Centers for Medicare and Medicaid Services. Medicare Part D Drug Coverage. Accessed May 2026.
- KFF (Kaiser Family Foundation). Changes to Medicare Part D Under the Inflation Reduction Act. 2024.
- HIV.gov (US Department of Health and Human Services). HIV Treatment — Living with HIV. Accessed May 2026.
- Centers for Disease Control and Prevention. HIV Treatment as Prevention. Accessed May 2026.
- US Food and Drug Administration. BIKTARVY Prescribing Information (FDA Label). Accessed May 2026.
- Health Resources and Services Administration. 340B Drug Pricing Program — Office of Pharmacy Affairs. Accessed May 2026.